title: Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.
abstract: OBJECTIVE
  Patients with chronic lymphocytic leukemia (CLL) and 17p deletion (17p-) have a poor prognosis. Although allogeneic hematopoietic stem-cell transplantation (HCT) has the potential to cure patients with advanced CLL, it is not known whether this holds true for patients with 17p-CLL.
  
  
  METHODS
  Baseline data from patients, for whom information on the presence of 17p-CLL was available, were downloaded from the European Group for Blood and Marrow Transplantation database. Additional information on the course of CLL and follow-up was collected with a questionnaire.
  
  
  RESULTS
  A total of 44 patients with 17p-CLL received allogeneic HCT between March 1995 and July 2006 from a matched sibling (n = 24) or an alternative donor (n = 20). 17p-CLL had been diagnosed by fluorescent in situ hybridization in 82% of patients and by conventional banding in 18% of patients. The median age was 54 years. Before HCT, a median of three lines of chemotherapy had been administered. At HCT, 53% of patients were in remission. Reduced-intensity conditioning was applied in 89% of patients. Acute, grade 2 to 4 graft-versus-host disease (GVHD) occurred in 43% of patients, and extensive chronic GVHD occurred in 53% of patients. At last follow-up, 19 patients were alive, with a median observation time of 39 months (range, 18 to 101 months). Three-year overall survival and progression-free survival rates were 44% and 37%, respectively. The cumulative incidence of progressive disease at 4 years was 34%. No late relapse occurred in nine patients with a follow-up longer than 4 years.
  
  
  CONCLUSIONS
  Allogeneic HCT has the potential to induce long-term disease-free survival in patients with 17p-CLL.
authors: University Hospital Carl Gustav Carus, Medizinische Klinik und Poliklinik I, Dresden, Germany. johannes.schetelig@uniklinikum-dresden.de
authors: Johannes
authors: J
authors: Schetelig
authors: Anja
authors: A
authors: van Biezen
authors: Ronald
authors: R
authors: Brand
authors: Dolores
authors: D
authors: Caballero
authors: Rodrigo
authors: R
authors: Martino
authors: Maija
authors: M
authors: Itala
authors: José A
authors: JA
authors: García-Marco
authors: Liisa
authors: L
authors: Volin
authors: Norbert
authors: N
authors: Schmitz
authors: Rainer
authors: R
authors: Schwerdtfeger
authors: Arnold
authors: A
authors: Ganser
authors: Francesco
authors: F
authors: Onida
authors: Brigitte
authors: B
authors: Mohr
authors: Stephan
authors: S
authors: Stilgenbauer
authors: Martin
authors: M
authors: Bornhäuser
authors: Theo
authors: T
authors: de Witte
authors: Peter
authors: P
authors: Dreger
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002872:Chromosome Deletion; D002886:Chromosomes, Human, Pair 17; D018572:Disease-Free Survival; D005060:Europe; D005260:Female; D015973:Gene Expression Regulation, Leukemic; D006086:Graft vs Host Disease / Q000209:etiology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics / Q000401:mortality / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D012042:Registries; D012189:Retrospective Studies; D011795:Surveys and Questionnaires; D013997:Time Factors; D014184:Transplantation, Homologous; D017211:Treatment Failure; D016896:Treatment Outcome